VCP and neoplasm: Small-molecule inhibitors that target p97, such as a metabolite of the clinically used disulfiram (CuET) and the orally bioavailable CB-5083, considerably enhanced PARPi sensitivity in HR-defective tumour cells and patient-derived tumour organoids, and may have clinical potential.